Causality of small and large intestinal microbiota in weight regulation and insulin resistance

Molecular Metabolism

Volumn 5, Issue 9, 2016, Pages 759-770

  Scheithauer, Torsten P M ^a,b,c   Dallinga Thie, Geesje M ^a   de Vos, Willem M ^d   Nieuwdorp, Max ^a,b,c   van Raalte, Daniël H ^b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Diabetes; Gut microbiota; Insulin resistance; Obesity; Weight regulation

Indexed keywords

ANTIBIOTIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; METFORMIN; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

ARTICLE; BACTERIAL METABOLISM; BACTERIAL TRANSLOCATION; BARIATRIC SURGERY; CAUSALITY; DIABETES MELLITUS; ENERGY YIELD; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LARGE INTESTINE; LIPID DIET; MICROBIAL COMMUNITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; SATIETY; SMALL INTESTINE; SYMBIOSIS; WEIGHT CONTROL;

EID: 84991071159     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.06.002     Document Type: Article

References (159)

1. [1] Smyth, S., Heron, A., Diabetes and obesity: the twin epidemics. Nature Medicine 12:1 (2006), 75–80.
2. [2] Astrup, A., Finer, N., Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’?. Obesity Reviews 1:2 (2000), 57–59.
3. [3] Krug, E.G., Trends in diabetes: sounding the alarm. The Lancet 387:10027 (2016), 1485–1486.
4. [4] World Health Organization, Global report on diabetes., 2016 France.
5. [5] Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:9945 (2014), 766–781.
6. [6] International Diabetes Federation, Diabetes Atlas. 7th ed, 2015.
7. [7] World Health Organization, Global status report on noncommunicable diseases., 2014 Geneva.
8. [8] Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3(11), 2006, e442.
9. [9] World Health Organization, Global health estimates summary tables: projection of deaths by cause, age and sex. 2013 Geneva.
10. [10] Tremaroli, V., Backhed, F., Functional interactions between the gut microbiota and host metabolism. Nature 489:7415 (2012), 242–249.
11. [11] Cani, P.D., Delzenne, N.M., The role of the gut microbiota in energy metabolism and metabolic disease. Current Pharmaceutical Design 15:13 (2009), 1546–1558.
12. [12] Zoetendal, E.G., Collier, C.T., Koike, S., Mackie, R.I., Gaskins, H.R., Molecular ecological analysis of the gastrointestinal microbiota: a review. Journal of Nutrition 134:2 (2004), 465–472.
13. [13] Muyzer, G., de Waal, E.C., Uitterlinden, A.G., Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Applied and Environmental Microbiology 59:3 (1993), 695–700.
14. [14] Whitman, W.B., Coleman, D.C., Wiebe, W.J., Prokaryotes: the unseen majority. Proceedings of the National Academy of Sciences of the United States of America 95:12 (1998), 6578–6583.
15. [15] Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature 464:7285 (2010), 59–65.
16. [16] Ley, R.E., Peterson, D.A., Gordon, J.I., Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124:4 (2006), 837–848.
17. [17] Jandhyala, S.M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., Reddy, D.N., Role of the normal gut microbiota. World Journal of Gastroenterology 21:29 (2015), 8787–8803.
18. [18] Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., Diversity of the human intestinal microbial flora. Science 308:5728 (2005), 1635–1638.
19. [19] O'Hara, A.M., Shanahan, F., The gut flora as a forgotten organ. EMBO Reports 7:7 (2006), 688–693.
20. [20] Rajilić-Stojanović, M., de Vos, W.M., The first 1000 cultured species of the human gastrointestinal microbiota. Fems Microbiology Reviews 38:5 (2014), 996–1047.
21. [21] Falony, G., Joossens, M., Vierira-Silva, S., Wang, J., Darzi, Y., Faust, K., et al. Population-level analysis of gut microbiome variation. Science 352:6285 (2016), 560–564.
22. [22] Faith, J.J., Guruge, J.L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A.L., et al. The long-term stability of the human gut microbiota. Science, 341(6141), 2013.
23. [23] Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C., Knight, R., Gordon, J.I., The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 449:7164 (2007), 804–810.
24. [24] Costello, E.K., Lauber, C.L., Hamady, M., Fierer, N., Gordon, J.I., Knight, R., Bacterial community variation in human body habitats across space and time. Science 326:5960 (2009), 1694–1697.
25. [25] Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 489:7415 (2012), 220–230.
26. [26] Semenkovich, C.F., Danska, J., Darsow, T., Dunne, J.L., Huttenhower, C., Insel, R.A., et al. American diabetes association and JDRF Research Symposium: diabetes and the microbiome. Diabetes 64:12 (2015), 3967–3977.
27. [27] Browne, H.P., Forster, S.C., Anonye, B.O., Kumar, N., Neville, B.A., Stares, M.D., et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature, 2016 [advance online publication].
28. [28] Frank, D.N., St. Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America 104:34 (2007), 13780–13785.
29. [29] Sekirov, I., Russell, S.L., Antunes, L.C., Finlay, B.B., Gut microbiota in health and disease. Physiological Reviews 90:3 (2010), 859–904.
30. [30] Belzer, C., de Vos, W.M., Microbes inside–from diversity to function: the case of Akkermansia. ISME Journal 6:8 (2012), 1449–1458.
31. [31] Gu, S., Chen, D., Zhang, J.-N., Lv, X., Wang, K., Duan, L.-P., et al. Bacterial community mapping of the mouse gastrointestinal tract. PLoS One, 8(10), 2013, e74957.
32. [32] Donaldson, G.P., Lee, S.M., Mazmanian, S.K., Gut biogeography of the bacterial microbiota. Nature Reviews Microbiology 14:1 (2016), 20–32.
33. [33] Swidsinski, A., Loening-Baucke, V., Lochs, H., Hale, L.P., Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World Journal of Gastroenterology 11:8 (2005), 1131–1140.
34. [34] Zoetendal, E.G., Raes, J., van den Bogert, B., Arumugam, M., Booijink, C.C.G.M., Troost, F.J., et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. The ISME Journal 6:7 (2012), 1415–1426.
35. [35] Chassard, C., Lacroix, C., Carbohydrates and the human gut microbiota. Current Opinion in Clinical Nutrition and Metabolic Care 16:4 (2013), 453–460.
36. [36] Louis, P., Scott, K.P., Duncan, S.H., Flint, H.J., Understanding the effects of diet on bacterial metabolism in the large intestine. Journal of Applied Microbiology 102:5 (2007), 1197–1208.
37. [37] Peng, L., He, Z., Chen, W., Holzman, I.R., Lin, J., Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatric Research 61:1 (2007), 37–41.
38. [38] Gao, Z., Yin, J., Zhang, J., Ward, R.E., Martin, R.J., Lefevre, M., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58:7 (2009), 1509–1517.
39. [39] Janssen, A.W., Kersten, S., The role of the gut microbiota in metabolic health. FASEB Journal 29:8 (2015), 3111–3123.
40. [40] Ramakrishna, B.S., Role of the gut microbiota in human nutrition and metabolism. Journal of Gastroenterology and Hepatology 28:Suppl 4 (2013), 9–17.
41. [41] LeBlanc, J.G., Milani, C., de Giori, G.S., Sesma, F., van Sinderen, D., Ventura, M., Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Current Opinion In Biotechnology 24:2 (2013), 160–168.
42. [42] Maurice, C.F., Haiser, H.J., Turnbaugh, P.J., Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:1–2 (2013), 39–50.
43. [43] Spanogiannopoulos, P., Bess, E.N., Carmody, R.N., Turnbaugh, P.J., The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nature Reviews Microbiology 14:5 (2016), 273–287.
44. [44] Mueller, D.M., Allenspach, M., Othman, A., Saely, C.H., Muendlein, A., Vonbank, A., et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 243:2 (2015), 638–644.
45. [45] Hooper, L.V., Littman, D.R., Macpherson, A.J., Interactions between the microbiota and the immune system. Science 336:6086 (2012), 1268–1273.
46. [46] Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature Reviews Immunology 14:3 (2014), 141–153.
47. [47] Martin, R., Miquel, S., Chain, F., Natividad, J.M., Jury, J., Lu, J., et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiology, 15, 2015, 67.
48. [48] Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences 110:22 (2013), 9066–9071.
49. [49] Round, J.L., Mazmanian, S.K., The gut microbiome shapes intestinal immune responses during health and disease. Nature Reviews Immunology 9:5 (2009), 313–323.
50. [50] Johansson, M.E.V., Jakobsson, H.E., Holmén-Larsson, J., Schütte, A., Ermund, A., Rodríguez-Piñeiro, A.M., et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host & Microbe 18:5 (2015), 582–592.
51. [51] Liu, S., da Cunha, A.P., Rezende, R.M., Cialic, R., Wei, Z., Bry, L., et al. The host shapes the gut microbiota via fecal microRNA. Cell Host & Microbe 19:1 (2016), 32–43.
52. [52] Fanning, S., Hall, L.J., Cronin, M., Zomer, A., MacSharry, J., Goulding, D., et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proceedings of the National Academy of Sciences of the United States of America 109:6 (2012), 2108–2113.
53. [53] Jeon, S.G., Kayama, H., Ueda, Y., Takahashi, T., Asahara, T., Tsuji, H., et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLOS Pathogens, 8(5), 2012, e1002714.
54. [54] Round, J.L., Mazmanian, S.K., Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proceedings of the National Academy of Sciences of the United States of America 107:27 (2010), 12204–12209.
55. [55] Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:6015 (2011), 337–341.
56. [56] Ivanov II, Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:3 (2009), 485–498.
57. [57] Pabst, O., Cerovic, V., Hornef, M., Secretory IgA in the coordination of establishment and maintenance of the microbiota. Trends in Immunology, 2016.
58. [58] Hammami, R., Fernandez, B., Lacroix, C., Fliss, I., Anti-infective properties of bacteriocins: an update. Cellular and Molecular Life Sciences 70:16 (2013), 2947–2967.
59. [59] Duncan, S.H., Louis, P., Thomson, J.M., Flint, H.J., The role of pH in determining the species composition of the human colonic microbiota. Environmental Microbiology 11:8 (2009), 2112–2122.
60. [60] Gantois, I., Ducatelle, R., Pasmans, F., Haesebrouck, F., Hautefort, I., Thompson, A., et al. Butyrate specifically down-regulates salmonella pathogenicity island 1 gene expression. Applied and Environmental Microbiology 72:1 (2006), 946–949.
61. [61] Vaishnava, S., Behrendt, C.L., Ismail, A.S., Eckmann, L., Hooper, L.V., Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proceedings of the National Academy of Sciences of the United States of America 105:52 (2008), 20858–20863.
62. [62] Kamada, N., Seo, S.U., Chen, G.Y., Nunez, G., Role of the gut microbiota in immunity and inflammatory disease. Nature Reviews Immunology 13:5 (2013), 321–335.
63. [63] Kamada, N., Chen, G.Y., Inohara, N., Nunez, G., Control of pathogens and pathobionts by the gut microbiota. Nature Immunology 14:7 (2013), 685–690.
64. [64] Scott, K.P., Gratz, S.W., Sheridan, P.O., Flint, H.J., Duncan, S.H., The influence of diet on the gut microbiota. Pharmacological Research 69:1 (2013), 52–60.
65. [65] Zhernakova, A., Kurilshikov, A., Bonder, M.J., Tigchelaar, E.F., Schirmer, M., Vatanen, T., et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352:6285 (2016), 565–569.
66. [66] Suez, J., Korem, T., Zeevi, D., Zilberman-Schapira, G., Thaiss, C.A., Maza, O., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514:7521 (2014), 181–186.
67. [67] Chassaing, B., Koren, O., Goodrich, J.K., Poole, A.C., Srinivasan, S., Ley, R.E., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519:7541 (2015), 92–96.
68. [68] Turnbaugh, P.J., Backhed, F., Fulton, L., Gordon, J.I., Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host & Microbe 3:4 (2008), 213–223.
69. [69] Korpela, K., Salonen, A., Virta, L.J., Kekkonen, R.A., Forslund, K., Bork, P., et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nature Communications, 7, 2016.
70. [70] Gerber, J.S., Bryan, M., Ross, R.K., Daymont, C., Parks, E.P., Localio, A.R., et al. Antibiotic exposure during the first 6 months of life and weight gain during childhood. JAMA 315:12 (2016), 1258–1265.
71. [71] Dominguez-Bello, M.G., De Jesus-Laboy, K.M., Shen, N., Cox, L.M., Amir, A., Gonzalez, A., et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nature Medicine 22:3 (2016), 250–253.
72. [72] Yatsunenko, T., Rey, F.E., Manary, M.J., Trehan, I., Dominguez-Bello, M.G., Contreras, M., et al. Human gut microbiome viewed across age and geography. Nature 486:7402 (2012), 222–227.
73. [73] Tamboli, C.P., Neut, C., Desreumaux, P., Colombel, J.F., Dysbiosis in inflammatory bowel disease. Gut 53:1 (2004), 1–4.
74. [74] Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158:4 (2014), 705–721.
75. [75] Shin, N.R., Lee, J.C., Lee, H.Y., Kim, M.S., Whon, T.W., Lee, M.S., et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:5 (2014), 727–735.
76. [76] Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:7581 (2015), 262–266.
77. [77] Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology 10:3 (2014), 143–156.
78. [78] Duca, F.A., Cote, C.D., Rasmussen, B.A., Zadeh-Tahmasebi, M., Rutter, G.A., Filippi, B.M., et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Medicine 21:5 (2015), 506–511.
79. [79] Rabot, S., Membrez, M., Bruneau, A., Gerard, P., Harach, T., Moser, M., et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB Journal 24:12 (2010), 4948–4959.
80. [80] Fleissner, C.K., Huebel, N., Abd El-Bary, M.M., Loh, G., Klaus, S., Blaut, M., Absence of intestinal microbiota does not protect mice from diet-induced obesity. British Journal of Nutrition 104:6 (2010), 919–929.
81. [81] Maslowski, K.M., Vieira, A.T., Ng, A., Kranich, J., Sierro, F., Yu, D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:7268 (2009), 1282–1286.
82. [82] Hoverstad, T., Midtvedt, T., Short-chain fatty acids in germfree mice and rats. Journal of Nutrition 116:9 (1986), 1772–1776.
83. [83] Bäckhed, F., Manchester, J.K., Semenkovich, C.F., Gordon, J.I., Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America 104:3 (2007), 979–984.
84. [84] Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of America 101:44 (2004), 15718–15723.
85. [85] Keith, S.W., Redden, D.T., Katzmarzyk, P.T., Boggiano, M.M., Hanlon, E.C., Benca, R.M., et al. Putative contributors to the secular increase in obesity: exploring the roads less traveled. International Journal of Obesity (London) 30:11 (2006), 1585–1594.
86. [86] Mattijssen, F., Alex, S., Swarts, H.J., Groen, A.K., van Schothorst, E.M., Kersten, S., Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion. Molecular Metabolism 3:2 (2014), 135–144.
87. [87] Robciuc, M.R., Naukkarinen, J., Ortega-Alonso, A., Tyynismaa, H., Raivio, T., Rissanen, A., et al. Serum angiopoietin-like 4 protein levels and expression in adipose tissue are inversely correlated with obesity in monozygotic twins. Journal of Lipid Research 52:8 (2011), 1575–1582.
88. [88] Kim, H.K., Youn, B.S., Shin, M.S., Namkoong, C., Park, K.H., Baik, J.H., et al. Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight. Diabetes 59:11 (2010), 2772–2780.
89. [89] Hardie, D.G., Carling, D., The AMP-activated protein kinase–fuel gauge of the mammalian cell?. European Journal of Biochemistry 246:2 (1997), 259–273.
90. [90] Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America 102:31 (2005), 11070–11075.
91. [91] Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., Gordon, J.I., The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Science Translational Medicine, 1(6), 2009, 6ra14.
92. [92] Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., Keilbaugh, S.A., Hamady, M., Chen, Y.Y., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137:5 (2009), 1716.e1-2–1724.e1-2.
93. [93] Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:7122 (2006), 1027–1131.
94. [94] Turnbaugh, P.J., Backhed, F., Fulton, L., Gordon, J.I., Marked alterations in the distal gut microbiome linked to diet-induced obesity. Cell Host & microbe 3:4 (2008), 213–223.
95. [95] Schwiertz, A., Taras, D., Schafer, K., Beijer, S., Bos, N.A., Donus, C., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18:1 (2010), 190–195.
96. [96] Murphy, E.F., Cotter, P.D., Healy, S., Marques, T.M., O'Sullivan, O., Fouhy, F., et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59:12 (2010), 1635–1642.
97. [97] Fernandes, J., Su, W., Rahat-Rozenbloom, S., Wolever, T.M.S., Comelli, E.M., Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutrition & Diabetes, 4, 2014, e121.
98. [98] Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 444:7122 (2006), 1022–1023.
99. [99] Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., et al. A core gut microbiome in obese and lean twins. Nature 457:7228 (2009), 480–484.
100. [100] Zhang, H., DiBaise, J.K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., et al. Human gut microbiota in obesity and after gastric bypass. Proceedings of the National Academy of Sciences, 2009.
101. [101] Samuel, B.S., Shaito, A., Motoike, T., Rey, F.E., Backhed, F., Manchester, J.K., et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences of the United States of America 105:43 (2008), 16767–16772.
102. [102] Batterham, R.L., Heffron, H., Kapoor, S., Chivers, J.E., Chandarana, K., Herzog, H., et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metabolism 4:3 (2006), 223–233.
103. [103] Batterham, R.L., Cohen, M.A., Ellis, S.M., Le Roux, C.W., Withers, D.J., Frost, G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine 349:10 (2003), 941–948.
104. [104] Cani, P.D., Lecourt, E., Dewulf, E.M., Sohet, F.M., Pachikian, B.D., Naslain, D., et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. American Journal of Clinical Nutrition 90:5 (2009), 1236–1243.
105. [105] Tolhurst, G., Heffron, H., Lam, Y.S., Parker, H.E., Habib, A.M., Diakogiannaki, E., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:2 (2012), 364–371.
106. [106] Hwang, I., Park, Y.J., Kim, Y.R., Kim, Y.N., Ka, S., Lee, H.Y., et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB Journal 29:6 (2015), 2397–2411.
107. [107] Drucker, D.J., Erlich, P., Asa, S.L., Brubaker, P.L., Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proceedings of the National Academy of Sciences of the United States of America 93:15 (1996), 7911–7916.
108. [108] Lam, Y.Y., Ha, C.W., Campbell, C.R., Mitchell, A.J., Dinudom, A., Oscarsson, J., et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One, 7(3), 2012, e34233.
109. [109] Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:6 (2008), 1470–1481.
110. [110] Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:11 (2007), 2374–2383.
111. [111] Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:8 (2009), 1091–1103.
112. [112] Bomhof, M.R., Saha, D.C., Reid, D.T., Paul, H.A., Reimer, R.A., Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats. Obesity (Silver Spring) 22:3 (2014), 763–771.
113. [113] Geloneze, B., Lima, M.M., Pareja, J.C., Barreto, M.R., Magro, D.O., Association of insulin resistance and GLP-2 secretion in obesity: a pilot study. Arquivos Brasileiros de Endocrinologia e Metabologia 57:8 (2013), 632–635.
114. [114] Russo, F., Linsalata, M., Clemente, C., Chiloiro, M., Orlando, A., Marconi, E., et al. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutrition Research 32:12 (2012), 940–946.
115. [115] Lin, H.V., Frassetto, A., Kowalik, E.J. Jr., Nawrocki, A.R., Lu, M.M., Kosinski, J.R., et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One, 7(4), 2012, e35240.
116. [116] Cani, P.D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N.M., Druart, C., et al. Endocannabinoids [mdash] at the crossroads between the gut microbiota and host metabolism. Nature Reviews Endocrinology 12:3 (2016), 133–143.
117. [117] Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:6830 (2001), 822–825.
118. [118] Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation 115:5 (2005), 1298–1305.
119. [119] Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rossner, S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:9468 (2005), 1389–1397.
120. [120] Jourdan, T., Godlewski, G., Cinar, R., Bertola, A., Szanda, G., Liu, J., et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nature Medicine 19:9 (2013), 1132–1140.
121. [121] Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 13:1 (2007), 35–37.
122. [122] Muccioli, G.G., Naslain, D., Backhed, F., Reigstad, C.S., Lambert, D.M., Delzenne, N.M., et al. The endocannabinoid system links gut microbiota to adipogenesis. Molecular Systems Biology, 6, 2010, 392.
123. [123] Geurts, L., Muccioli, G.G., Delzenne, N.M., Cani, P.D., Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia. PLoS One, 8(2), 2013, e55963.
124. [124] Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:7 (2007), 1761–1772.
125. [125] Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:7418 (2012), 55–60.
126. [126] Larsen, N., Vogensen, F.K., van den Berg, F.W.J., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 5(2), 2010, e9085.
127. [127] Hawkesworth, S., Moore, S.E., Fulford, A.J.C., Barclay, G.R., Darboe, A.A., Mark, H., et al. Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutrition & Diabetes, 3, 2013, e83.
128. [128] Zarember, K.A., Godowski, P.J., Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. Journal of Immunology 168:2 (2002), 554–561.
129. [129] Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., Flier, J.S., TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 116:11 (2006), 3015–3025.
130. [130] Liang, H., Hussey, S.E., Sanchez-Avila, A., Tantiwong, P., Musi, N., Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One, 8(5), 2013, e63983.
131. [131] Lackey, D.E., Olefsky, J.M., Regulation of metabolism by the innate immune system. Nature Reviews Endocrinology 12:1 (2016), 15–28.
132. [132] Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermúdez-Humarán, L.G., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Molecular Medicine, 2011, 3.
133. [133] Amar, J., Serino, M., Lange, C., Chabo, C., Iacovoni, J., Mondot, S., et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia, 54, 2011.
134. [134] Neal, M.D., Leaphart, C., Levy, R., Prince, J., Billiar, T.R., Watkins, S., et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. Journal of Immunology 176:5 (2006), 3070–3079.
135. [135] Fei, N., Zhao, L., An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. The ISME Journal 7:4 (2013), 880–884.
136. [136] Wu, X., Ma, C., Han, L., Nawaz, M., Gao, F., Zhang, X., et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Current Microbiology 61:1 (2010), 69–78.
137. [137] O'Mahony, D., Murphy, S., Boileau, T., Park, J., O'Brien, F., Groeger, D., et al. Bifidobacterium animalis AHC7 protects against pathogen-induced NF-κB activation in vivo. BMC Immunology 11:1 (2010), 1–9.
138. [138] Furet, J.P., Kong, L.C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.L., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:12 (2010), 3049–3057.
139. [139] Ejtahed, H.S., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asghari-Jafarabadi, M., Mofid, V., Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 28:5 (2012), 539–543.
140. [140] Mikelsaar, M., Zilmer, M., Lactobacillus fermentum ME-3 – an antimicrobial and antioxidative probiotic. Microbial Ecology in Health and Disease 21:1 (2009), 1–27.
141. [141] Mohamadshahi, M., Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. Bioimpacts 4:2 (2014), 83–88.
142. [142] Andreasen, A.S., Larsen, N., Pedersen-Skovsgaard, T., Berg, R.M., Moller, K., Svendsen, K.D., et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. British Journal of Nutrition 104:12 (2010), 1831–1838.
143. [143] Karczewski, J., Troost, F.J., Konings, I., Dekker, J., Kleerebezem, M., Brummer, R.J., et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American Journal of Physiology Gastrointestinal and Liver Physiology 298:6 (2010), G851–G859.
144. [144] Van den Abbeele, P., Belzer, C., Goossens, M., Kleerebezem, M., De Vos, W.M., Thas, O., et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. The ISME Journal 7:5 (2013), 949–961.
145. [145] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 368:5 (2013), 407–415.
146. [146] Vrieze, A., Van Nood, E., Holleman, F., Salojarvi, J., Kootte, R.S., Bartelsman, J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 143(4), 2012 913.e7–916.e7.
147. [147] Abdeen, G., le Roux, C.W., Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. Review. Obesity Surgery 26:2 (2016), 410–421.
148. [148] Madsbad, S., Dirksen, C., Holst, J.J., Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. The Lancet Diabetes & Endocrinology 2:2 (2014), 152–164.
149. [149] le Roux, C.W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 246:5 (2007), 780–785.
150. [150] Fiorucci, S., Distrutti, E., Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends in Molecular Medicine 21:11 (2015), 702–714.
151. [151] Schaap, F.G., Trauner, M., Jansen, P.L.M., Bile acid receptors as targets for drug development. Nature Reviews Gastroenterology & Hepatology 11:1 (2014), 55–67.
152. [152] Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10:3 (2009), 167–177.
153. [153] Penney, N.C., Kinross, J., Newton, R.C., Purkayastha, S., The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. International Journal of Obesity 39:11 (2015), 1565–1574.
154. [154] Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:7499 (2014), 183–188.
155. [155] Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L.G., Gratadoux, J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America 105:43 (2008), 16731–16736.
156. [156] Graessler, J., Qin, Y., Zhong, H., Zhang, J., Licinio, J., Wong, M.L., et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. The Pharmacogenomics Journal 13:6 (2013), 514–522.
157. [157] Hartman, A.L., Lough, D.M., Barupal, D.K., Fiehn, O., Fishbein, T., Zasloff, M., et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proceedings of the National Academy of Sciences 106:40 (2009), 17187–17192.
158. [158] Liou, A.P., Paziuk, M., Luevano, J.M. Jr., Machineni, S., Turnbaugh, P.J., Kaplan, L.M., Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Science Translational Medicine, 5(178), 2013, 178ra41.
159. [159] de Vos, W.M., Nieuwdorp, M., Genomics: a gut prediction. Nature 498:7452 (2013), 48–49.